DDrare: Database of Drug Development for Rare Diseases

Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZD0530; AZD0530 Difumarate; Garetosmab; PALOVAROTENE; PALOVAROTENE - 1.5mg; PALOVAROTENE - 10 mg; PALOVAROTENE - 1mg; PALOVAROTENE - 2 mg; PALOVAROTENE - 2.5 mg; PALOVAROTENE - 3 mg; PALOVAROTENE - 4 mg; PALOVAROTENE - 5 mg; Palovarotene; Palovarotene dose level 1; Palovarotene dose level 2; Palovarotene dose level 3; Palovarotene dose level 4; Perhexiline; REGN2477; SARACATINIB DIFUMARATE; Saracatinib

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000019348	2010/07/01	14/10/2015	Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)		fibrodysplasia ossificans progressiva	oral administration of perhexiline maleate for one year	Nagoya University Graduate School of Medicine	NULL	Complete: follow-up complete	15years-old	65years-old	Male and Female	5	Phase 1;Phase 2	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000019348

2010/07/01

14/10/2015

Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)

fibrodysplasia ossificans progressiva

oral administration of perhexiline maleate for one year

Nagoya University Graduate School of Medicine

NULL

Complete: follow-up complete

15years-old

65years-old

Male and Female

Phase 1;Phase 2

Japan